Entia Biosciences (ERGO) Inactive 10-K2010 FY Annual report

Filed: 18 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: adapt, advisor, AF, aid, Alzheimer, analog, ApplicationNo, Aruba, ASC, Autogroup, automated, Bangalore, bankruptcy, Barrier, barring, bionutrient, Biopharma, biopharmaceutical, biotech, Bonaire, boost, Brain, Buick, Bunapi, canine, Capella, cereal, cholecalciferol, civil, Clemente, coenzyme, College, Cologne, Commodity, consent, constitute, conviction, Cordex, Curacao, curcumin, damage, death, decade, decree, DEFAULT, deployed, deploying, Depression, DEVOTE, Diego, diferuloylmethane, discovery, disinterested, Disorder, donor, dramatic, electron, element, embedded, employed, enjoining, entirety, EquiSANOTM, ergo, ergocalciferol, Europe, European, Evergreen, extracted, extraction, feet, fluctuate, force, formula, found, freestanding, fulfill, fulfillment, Germany, GlucoSANOTM, GMC, Groh, hair, holding, host, idebenone, ImmuSANOTM, inconsistent, India, Inflation, Injury, Instant, Intelligent, intercompany, IR, ISO, issuable, jeopardize, judgment, juice, Keith, Kingdom, Koch, Korea, lanolin, leaving, lethal, leverage, licensee, lieu, LLP, LTR, Manfred, margarine, Master, MATCH, melanogaster, metastatic, methodology, milestone, milk, Minnesota, modern, move, MSH, MSM, multi, Murill, muscle, nail, nonchemical, nonstatutory, NSO, NuFex, NuFlex, nutriceutical, NutriMedical, nutritionally, online, optimized, optionee, orange, Oregon, OTC, outsourced, pain, PCT, permissible, Pest, Peterson, petition, phasing, photochemical, platform, pocket, Pontiac, portfolio, possession, postage, predetermined, proceed, proceeding, Program, pursue, pursued, qualification, Quitman, quotation, ranging, rapidly, recommended, recommending, red, Repair, replacement, RESCHEDULING, reseller, revert, Salem, scavenge, shelf, Sherwood, showcase, Similarly, situation, slightly, social, South, spectrum, spice, spray, stable, standing, sublicensed, sublicensing, substantive, Sullivan, suppression, Suriname, suspended, suspending, synthetic, temporarily, Therapeutic, traffic, transporter, Traumatic, tumeric, turmeric, TX, type, typically, uncollectible, unenriched, Union, unique, unissued, unpaid, upgraded, upturn, vacated, valid, validate, verified, Vice, vigilant, vivo, week, Western, Willamette, wind, wrote

Removed: accomplish, afford, Arnone, assumed, attention, category, chain, Chartered, check, choose, comparability, confidentiality, convey, copyright, decided, differentiate, dilutive, earned, fail, fifteen, Frank, goal, grocery, launched, mark, message, Moore, noncontrolling, North, ongoing, organizational, organized, preclinical, prospectively, reformation, relied, reparation, run, seek, selected, small, spin, standard, submit, thought, traded, transition, twelve, unanimously, underlying, website

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ERGO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Total Nutraceutical Solutions, Inc. (the “Company”) for the fiscal year ended December 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Marvin S. Hausman, M.D., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 18, 2011	By: /s/ Marvin S. Hausman, M.D.
	Marvin S. Hausman, M.D.
	Chief Executive Officer

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.